- Conditions
- Endometrial Hyperplasia, Osteoporosis
- Interventions
- Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 1,083 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mammographic Density, Abnormal Mammogram
- Interventions
- CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 42 Years to 58 Years · Female only
- Enrollment
- 517 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Glucose Homeostasis, Postmenopausal Symptoms
- Interventions
- Bazedoxifene/Conjugated Estrogens (BZA/CE), Placebo Oral Tablet
- Drug
- Lead sponsor
- Tulane University Health Sciences Center
- Other
- Eligibility
- 50 Years to 60 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Menopause, Prediabetes, Obesity
- Interventions
- Placebo, conjugated estrogens/bazedoxifene (CE/BZA)
- Other · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 60 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Menopause
- Interventions
- Estradiol , estriol , progesterone, estradiol, progesterone, estriol, progesterone, equine estrogens m-progesteroneacetate
- Drug
- Lead sponsor
- Jeanne Drisko, MD, CNS, FACN
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Risk Reduction, Breast Cancer
- Interventions
- Bazedoxifene and Conjugated Estrogens
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 45 Years to 64 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Duarte, California • San Francisco, California • Chicago, Illinois + 3 more
- Conditions
- Breast Cancer
- Interventions
- Duavee
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- Up to 61 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Westwood, Kansas
- Conditions
- Osteoporosis
- Interventions
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
- Conditions
- Menopause, Osteoporosis
- Interventions
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 64 Years · Female only
- Enrollment
- 1,886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
- Conditions
- Postmenopause
- Interventions
- Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
- Conditions
- Increased Risk for Development of Breast Cancer
- Interventions
- bazedoxifene plus conjugated estrogens
- Drug
- Lead sponsor
- Carol Fabian, MD
- Other
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Focus of Study is Healthy Women at Risk for Breast Cancer
- Interventions
- DUAVEE 0.45Mg-20Mg Tablet
- Drug
- Lead sponsor
- Carol Fabian, MD
- Other
- Eligibility
- 45 Years to 60 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Menopause, Arteriosclerosis
- Interventions
- Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
- Drug
- Lead sponsor
- Kronos Longevity Research Institute
- Other
- Eligibility
- 42 Years to 58 Years · Female only
- Enrollment
- 728 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2012
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more